daminozide profile

daminozide: induces tumors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	15331
CHEMBL ID	2164243
CHEBI ID	4312
SCHEMBL ID	50347
MeSH ID	M0063036

Synonym
f6kf33m5ub ,
bernsteinsaeure-2,2-dimethylhydrazid
2,2-dimethylhydrazid kyseliny jantarove
unii-f6kf33m5ub
n-dimethylamino-succinamidsaeure
4-(2,2-dimethylhydrazino)-4-oxobutanoic acid
succinic acid, mono(2,2-dimethylhydrazide)
butanedioic acid, mono(2,2-dimethylhydrazide)
NCGC00091281-01
n-(dimethylamino)succinamic acid
brn 1863230
butanedioic acid mono(2,2-dimethylhydrazide)
kylar
succinic acid, 2,2-dimethylhydrazide
aminozide
dyak
succinic n',n'-dimethylhydrazide
einecs 216-485-9
caswell no. 808
dimethylaminosuccinamic acid
sadh
succinic acid 2,2-dimethylhydrazide
hsdb 1769
dimas
b-nine
2,2-dimethylhydrazid kyseliny jantarove [czech]
succinic 1,1-dimethyl hydrazide
epa pesticide chemical code 035101
dmasa
alar 85
ai3-50727
b 995
nci-c03827
bernsteinsaeure-2,2-dimethylhydrazid [german]
n-dimethylamino-succinamidsaeure [german]
daminozide [ansi:bsi:iso]
n-dimethylamino-beta-carbamylpropionic acid
ccris 191
succinic acid n,n-dimethylhydrazide
daminozide
1596-84-5
SR-01000644985-1
NCGC00091281-02
succinic acid-2,2-dimethylhydrazide
alar
NCGC00091281-03
4-(2,2-dimethylhydrazinyl)-4-oxobutanoic acid
NCGC00091281-04
NCGC00091281-05
D4015
NCGC00259748-01
dtxsid9020370 ,
tox21_300919
cas-1596-84-5
dtxcid70370
NCGC00254822-01
tox21_202199
AKOS005208038
CCG-55990
CHEMBL2164243 ,
chebi:4312 ,
bdbm50395076
HY-13643
CS-1288
FT-0629276
NCGC00091281-07
S4800
c6h12n2o3
gtpl7025
3-(n',n'-dimethylhydrazinecarbonyl)propanoic acid
daminozide [mi]
1-(2,2-dimethylhydrazide)butanedioic acid
b-995
daminozide [hsdb]
2,2-dimethylhydrazine succinic acid
daminozide [iso]
SCHEMBL50347
MLS006012018
smr000777919
dazide
4-(2,2-dimethylhydrazino)-4-oxobutanoic acid #
succinic acid, n,n-dimethylhydrazide
NOQGZXFMHARMLW-UHFFFAOYSA-N
aminozid
succinic acid, mono-2,2-dimethylhydrazine
4-(2,2-dimethylhydrazino)-4-oxo-butanoic acid
W-107985
HB1404
1-(2,2-dimethylhydrazide)butanedioi c acid
mfcd00002787
daminozide, pestanal(r), analytical standard
Q424372
STR04971
HMS3426I11
butanedioic acid, 1-(2,2-dimethylhydrazide)
H10499
butanedioic acid, mono (2,2-dimethylhydrazide)
EN300-4290280
Z1255457389

Excerpt	Reference	Relevance
" The aim of the present study was to assess the carcinogenicity of daminozide alone and in combination with 1,1-dimethylhydrazine (UDMH), its major contaminant, in a novel medium-term bioassay in Fischer 344 rats, the DEN-PH model."	( Lack of carcinogenicity of daminozide, alone or in combination with its contaminant 1,1-dimethylhydrazine, in a medium-term bioassay. Cabral, R; Hakoi, K; Hasegawa, R; Hoshiya, T; Ito, N, )	0.13

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Class	Description
straight-chain fatty acid	Any fatty acid whose skeletal carbon atoms form an unbranched open chain.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	0.7943	0.0032	45.4673	12,589.2998	AID2517
SMAD family member 2	Homo sapiens (human)	Potency	3.0896	0.1737	34.3047	61.8120	AID1346924
SMAD family member 3	Homo sapiens (human)	Potency	3.0896	0.1737	34.3047	61.8120	AID1346924
EWS/FLI fusion protein	Homo sapiens (human)	Potency	30.0575	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	24.9502	0.0008	17.5051	59.3239	AID1159527
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	0.0015	0.0015	30.6073	15,848.9004	AID1224849
pregnane X nuclear receptor	Homo sapiens (human)	Potency	31.6228	0.0054	28.0263	1,258.9301	AID720659
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	22.3399	0.0002	29.3054	16,493.5996	AID743075; AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Lysine-specific demethylase 4E	Homo sapiens (human)	IC50 (µMol)	100.0000	0.2000	1.9569	6.3096	AID698697
Lysine-specific demethylase 6B	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0160	1.6672	6.9000	AID698695
Lysine-specific demethylase 6A	Homo sapiens (human)	IC50 (µMol)	100.0000	0.2000	3.9017	9.0000	AID770455
Lysine-specific demethylase 4A	Homo sapiens (human)	IC50 (µMol)	3,300.0000	0.2000	2.8319	4.7600	AID770458
Gamma-butyrobetaine dioxygenase	Homo sapiens (human)	IC50 (µMol)	100.0000	0.6900	3.1645	7.9000	AID698692
Lysine-specific demethylase 5A	Homo sapiens (human)	IC50 (µMol)	2,200.0000	0.1300	2.3747	10.0000	AID770457
Lysine-specific demethylase 5C	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1600	2.6837	7.9433	AID698696
Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)	IC50 (µMol)	2,200.0000	0.0020	0.1438	1.5490	AID770457
Lysine-specific demethylase 7A	Homo sapiens (human)	IC50 (µMol)	2.1000	2.1000	2.1000	2.1000	AID698699
Prolyl 4-hydroxylase	Paramecium bursaria Chlorella virus 1	IC50 (µMol)	100.0000	5.0000	6.2667	8.5000	AID1543452
Egl nine homolog 1	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0070	1.8614	8.0000	AID698694
Lysine-specific demethylase 4C	Homo sapiens (human)	IC50 (µMol)	2,500.0000	0.1600	2.1148	9.4000	AID770459
Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)	IC50 (µMol)	100.0000	8.6000	8.6000	8.6000	AID698693
Histone lysine demethylase PHF8	Homo sapiens (human)	IC50 (µMol)	6.7000	0.2100	1.3620	3.2000	AID698701; AID770456; AID770460
Lysine-specific demethylase 2A	Homo sapiens (human)	IC50 (µMol)	1.5000	0.1600	2.4596	6.9000	AID698691; AID698700; AID770454
Lysine-specific demethylase 2A	Homo sapiens (human)	Ki	43.4850	1.9700	1.9700	1.9700	AID698677; AID698678
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of gene expression	Lysine-specific demethylase 4E	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 4E	Homo sapiens (human)
inflammatory response to antigenic stimulus	Lysine-specific demethylase 6B	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 6B	Homo sapiens (human)
response to activity	Lysine-specific demethylase 6B	Homo sapiens (human)
hippocampus development	Lysine-specific demethylase 6B	Homo sapiens (human)
cell fate commitment	Lysine-specific demethylase 6B	Homo sapiens (human)
endothelial cell differentiation	Lysine-specific demethylase 6B	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Lysine-specific demethylase 6B	Homo sapiens (human)
mesodermal cell differentiation	Lysine-specific demethylase 6B	Homo sapiens (human)
cardiac muscle cell differentiation	Lysine-specific demethylase 6B	Homo sapiens (human)
response to fungicide	Lysine-specific demethylase 6B	Homo sapiens (human)
cellular response to hydrogen peroxide	Lysine-specific demethylase 6B	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Lysine-specific demethylase 6B	Homo sapiens (human)
heart development	Lysine-specific demethylase 6B	Homo sapiens (human)
regulation of gene expression	Lysine-specific demethylase 6B	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 6A	Homo sapiens (human)
regulation of gene expression	Lysine-specific demethylase 6A	Homo sapiens (human)
heart development	Lysine-specific demethylase 6A	Homo sapiens (human)
negative regulation of autophagy	Lysine-specific demethylase 4A	Homo sapiens (human)
positive regulation of gene expression	Lysine-specific demethylase 4A	Homo sapiens (human)
negative regulation of gene expression	Lysine-specific demethylase 4A	Homo sapiens (human)
cardiac muscle hypertrophy in response to stress	Lysine-specific demethylase 4A	Homo sapiens (human)
apoptotic chromosome condensation	Lysine-specific demethylase 4A	Homo sapiens (human)
response to nutrient levels	Lysine-specific demethylase 4A	Homo sapiens (human)
positive regulation of neuron differentiation	Lysine-specific demethylase 4A	Homo sapiens (human)
negative regulation of DNA-templated transcription	Lysine-specific demethylase 4A	Homo sapiens (human)
negative regulation of astrocyte differentiation	Lysine-specific demethylase 4A	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 4A	Homo sapiens (human)
regulation of gene expression	Lysine-specific demethylase 4A	Homo sapiens (human)
carnitine biosynthetic process	Gamma-butyrobetaine dioxygenase	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Lysine-specific demethylase 5A	Homo sapiens (human)
circadian regulation of gene expression	Lysine-specific demethylase 5A	Homo sapiens (human)
positive regulation of DNA-templated transcription	Lysine-specific demethylase 5A	Homo sapiens (human)
regulation of DNA-binding transcription factor activity	Lysine-specific demethylase 5A	Homo sapiens (human)
facultative heterochromatin formation	Lysine-specific demethylase 5A	Homo sapiens (human)
regulation of DNA-templated transcription	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 5A	Homo sapiens (human)
response to toxic substance	Lysine-specific demethylase 5C	Homo sapiens (human)
negative regulation of DNA-templated transcription	Lysine-specific demethylase 5C	Homo sapiens (human)
rhythmic process	Lysine-specific demethylase 5C	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 5C	Homo sapiens (human)
regulation of DNA-templated transcription	Lysine-specific demethylase 5C	Homo sapiens (human)
protein peptidyl-prolyl isomerization	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein phosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein phosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein folding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein kinase activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
apoptotic process	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
viral release from host cell	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
platelet activation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
neuron differentiation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
neutrophil chemotaxis	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
leukocyte chemotaxis	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
activation of protein kinase B activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of stress-activated MAPK cascade	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
lipid droplet organization	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cellular response to oxidative stress	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein dephosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
endothelial cell activation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of MAPK cascade	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
regulation of viral genome replication	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of viral genome replication	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein secretion	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cell adhesion molecule production	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein K48-linked ubiquitination	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
platelet aggregation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of viral life cycle	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
regulation of apoptotic signaling pathway	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 7A	Homo sapiens (human)
midbrain development	Lysine-specific demethylase 7A	Homo sapiens (human)
positive regulation of DNA-templated transcription	Lysine-specific demethylase 7A	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Lysine-specific demethylase 7A	Homo sapiens (human)
protein demethylation	Lysine-specific demethylase 7A	Homo sapiens (human)
response to hypoxia	Egl nine homolog 1	Homo sapiens (human)
intracellular iron ion homeostasis	Egl nine homolog 1	Homo sapiens (human)
intracellular oxygen homeostasis	Egl nine homolog 1	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Egl nine homolog 1	Homo sapiens (human)
regulation of angiogenesis	Egl nine homolog 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Egl nine homolog 1	Homo sapiens (human)
negative regulation of cyclic-nucleotide phosphodiesterase activity	Egl nine homolog 1	Homo sapiens (human)
cardiac muscle tissue morphogenesis	Egl nine homolog 1	Homo sapiens (human)
heart trabecula formation	Egl nine homolog 1	Homo sapiens (human)
ventricular septum morphogenesis	Egl nine homolog 1	Homo sapiens (human)
labyrinthine layer development	Egl nine homolog 1	Homo sapiens (human)
response to nitric oxide	Egl nine homolog 1	Homo sapiens (human)
regulation of modification of postsynaptic structure	Egl nine homolog 1	Homo sapiens (human)
regulation protein catabolic process at postsynapse	Egl nine homolog 1	Homo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-proline	Egl nine homolog 1	Homo sapiens (human)
cellular response to hypoxia	Egl nine homolog 1	Homo sapiens (human)
blastocyst formation	Lysine-specific demethylase 4C	Homo sapiens (human)
positive regulation of cell population proliferation	Lysine-specific demethylase 4C	Homo sapiens (human)
stem cell population maintenance	Lysine-specific demethylase 4C	Homo sapiens (human)
androgen receptor signaling pathway	Lysine-specific demethylase 4C	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Lysine-specific demethylase 4C	Homo sapiens (human)
regulation of androgen receptor signaling pathway	Lysine-specific demethylase 4C	Homo sapiens (human)
regulation of stem cell differentiation	Lysine-specific demethylase 4C	Homo sapiens (human)
regulation of gene expression	Lysine-specific demethylase 4C	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 4C	Homo sapiens (human)
positive regulation of myoblast differentiation	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
negative regulation of Notch signaling pathway	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
positive regulation of vasculogenesis	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Histone lysine demethylase PHF8	Homo sapiens (human)
chromatin remodeling	Histone lysine demethylase PHF8	Homo sapiens (human)
brain development	Histone lysine demethylase PHF8	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone lysine demethylase PHF8	Homo sapiens (human)
positive regulation of transcription by RNA polymerase I	Histone lysine demethylase PHF8	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone lysine demethylase PHF8	Homo sapiens (human)
negative regulation of rDNA heterochromatin formation	Histone lysine demethylase PHF8	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Histone lysine demethylase PHF8	Homo sapiens (human)
protein demethylation	Histone lysine demethylase PHF8	Homo sapiens (human)
double-strand break repair via nonhomologous end joining	Lysine-specific demethylase 2A	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 2A	Homo sapiens (human)
negative regulation of transcription by competitive promoter binding	Lysine-specific demethylase 2A	Homo sapiens (human)
circadian regulation of gene expression	Lysine-specific demethylase 2A	Homo sapiens (human)
regulation of circadian rhythm	Lysine-specific demethylase 2A	Homo sapiens (human)
protein demethylation	Lysine-specific demethylase 2A	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Lysine-specific demethylase 2A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
metal ion binding	Lysine-specific demethylase 4E	Homo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activity	Lysine-specific demethylase 4E	Homo sapiens (human)
histone H3K9 demethylase activity	Lysine-specific demethylase 4E	Homo sapiens (human)
protein binding	Lysine-specific demethylase 6B	Homo sapiens (human)
beta-catenin binding	Lysine-specific demethylase 6B	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 6B	Homo sapiens (human)
metal ion binding	Lysine-specific demethylase 6B	Homo sapiens (human)
histone H3K27me2/H3K27me3 demethylase activity	Lysine-specific demethylase 6B	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Lysine-specific demethylase 6B	Homo sapiens (human)
chromatin DNA binding	Lysine-specific demethylase 6B	Homo sapiens (human)
protein binding	Lysine-specific demethylase 6A	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 6A	Homo sapiens (human)
metal ion binding	Lysine-specific demethylase 6A	Homo sapiens (human)
histone H3K27me2/H3K27me3 demethylase activity	Lysine-specific demethylase 6A	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Lysine-specific demethylase 6A	Homo sapiens (human)
chromatin DNA binding	Lysine-specific demethylase 6A	Homo sapiens (human)
protein binding	Lysine-specific demethylase 4A	Homo sapiens (human)
zinc ion binding	Lysine-specific demethylase 4A	Homo sapiens (human)
ubiquitin protein ligase binding	Lysine-specific demethylase 4A	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 4A	Homo sapiens (human)
methylated histone binding	Lysine-specific demethylase 4A	Homo sapiens (human)
histone H3K36 demethylase activity	Lysine-specific demethylase 4A	Homo sapiens (human)
histone H3K36me2/H3K36me3 demethylase activity	Lysine-specific demethylase 4A	Homo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activity	Lysine-specific demethylase 4A	Homo sapiens (human)
histone H3K9 demethylase activity	Lysine-specific demethylase 4A	Homo sapiens (human)
iron ion binding	Gamma-butyrobetaine dioxygenase	Homo sapiens (human)
protein binding	Gamma-butyrobetaine dioxygenase	Homo sapiens (human)
zinc ion binding	Gamma-butyrobetaine dioxygenase	Homo sapiens (human)
gamma-butyrobetaine dioxygenase activity	Gamma-butyrobetaine dioxygenase	Homo sapiens (human)
identical protein binding	Gamma-butyrobetaine dioxygenase	Homo sapiens (human)
transcription cis-regulatory region binding	Lysine-specific demethylase 5A	Homo sapiens (human)
DNA binding	Lysine-specific demethylase 5A	Homo sapiens (human)
transcription coactivator activity	Lysine-specific demethylase 5A	Homo sapiens (human)
enzyme inhibitor activity	Lysine-specific demethylase 5A	Homo sapiens (human)
protein binding	Lysine-specific demethylase 5A	Homo sapiens (human)
zinc ion binding	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin DNA binding	Lysine-specific demethylase 5A	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 5A	Homo sapiens (human)
histone H3K4me/H3K4me2/H3K4me3 demethylase activity	Lysine-specific demethylase 5A	Homo sapiens (human)
methylated histone binding	Lysine-specific demethylase 5A	Homo sapiens (human)
histone binding	Lysine-specific demethylase 5A	Homo sapiens (human)
DNA binding	Lysine-specific demethylase 5C	Homo sapiens (human)
protein binding	Lysine-specific demethylase 5C	Homo sapiens (human)
zinc ion binding	Lysine-specific demethylase 5C	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 5C	Homo sapiens (human)
histone H3K4 demethylase activity	Lysine-specific demethylase 5C	Homo sapiens (human)
histone H3K4me/H3K4me2/H3K4me3 demethylase activity	Lysine-specific demethylase 5C	Homo sapiens (human)
RNA binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
integrin binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cyclosporin A binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
virion binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
unfolded protein binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
heparan sulfate binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
iron ion binding	Lysine-specific demethylase 7A	Homo sapiens (human)
zinc ion binding	Lysine-specific demethylase 7A	Homo sapiens (human)
2-oxoglutarate-dependent dioxygenase activity	Lysine-specific demethylase 7A	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 7A	Homo sapiens (human)
histone H3K9 demethylase activity	Lysine-specific demethylase 7A	Homo sapiens (human)
methylated histone binding	Lysine-specific demethylase 7A	Homo sapiens (human)
histone H4K20 demethylase activity	Lysine-specific demethylase 7A	Homo sapiens (human)
histone H3K36 demethylase activity	Lysine-specific demethylase 7A	Homo sapiens (human)
histone H3K27me2/H3K27me3 demethylase activity	Lysine-specific demethylase 7A	Homo sapiens (human)
histone H3K9me/H3K9me2 demethylase activity	Lysine-specific demethylase 7A	Homo sapiens (human)
transcription coregulator activity	Lysine-specific demethylase 7A	Homo sapiens (human)
protein binding	Egl nine homolog 1	Homo sapiens (human)
ferrous iron binding	Egl nine homolog 1	Homo sapiens (human)
2-oxoglutarate-dependent dioxygenase activity	Egl nine homolog 1	Homo sapiens (human)
enzyme binding	Egl nine homolog 1	Homo sapiens (human)
L-ascorbic acid binding	Egl nine homolog 1	Homo sapiens (human)
peptidyl-proline dioxygenase activity	Egl nine homolog 1	Homo sapiens (human)
hypoxia-inducible factor-proline dioxygenase activity	Egl nine homolog 1	Homo sapiens (human)
peptidyl-proline 4-dioxygenase activity	Egl nine homolog 1	Homo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activity	Lysine-specific demethylase 4C	Homo sapiens (human)
zinc ion binding	Lysine-specific demethylase 4C	Homo sapiens (human)
enzyme binding	Lysine-specific demethylase 4C	Homo sapiens (human)
nuclear receptor coactivator activity	Lysine-specific demethylase 4C	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 4C	Homo sapiens (human)
histone H3K9 demethylase activity	Lysine-specific demethylase 4C	Homo sapiens (human)
nuclear androgen receptor binding	Lysine-specific demethylase 4C	Homo sapiens (human)
histone H3K36 demethylase activity	Lysine-specific demethylase 4C	Homo sapiens (human)
H3K9me3 modified histone binding	Lysine-specific demethylase 4C	Homo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activity	Lysine-specific demethylase 4C	Homo sapiens (human)
transcription corepressor activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
Notch binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
protein binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
ferrous iron binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
zinc ion binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
oxygen sensor activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
carboxylic acid binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
peptidyl-histidine dioxygenase activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
[protein]-asparagine 3-dioxygenase activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
protein homodimerization activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
NF-kappaB binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
peptidyl-aspartic acid 3-dioxygenase activity	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
ankyrin repeat binding	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
chromatin binding	Histone lysine demethylase PHF8	Homo sapiens (human)
iron ion binding	Histone lysine demethylase PHF8	Homo sapiens (human)
protein binding	Histone lysine demethylase PHF8	Homo sapiens (human)
zinc ion binding	Histone lysine demethylase PHF8	Homo sapiens (human)
2-oxoglutarate-dependent dioxygenase activity	Histone lysine demethylase PHF8	Homo sapiens (human)
histone demethylase activity	Histone lysine demethylase PHF8	Homo sapiens (human)
histone H3K9 demethylase activity	Histone lysine demethylase PHF8	Homo sapiens (human)
methylated histone binding	Histone lysine demethylase PHF8	Homo sapiens (human)
histone H4K20 demethylase activity	Histone lysine demethylase PHF8	Homo sapiens (human)
histone H3K36 demethylase activity	Histone lysine demethylase PHF8	Homo sapiens (human)
histone H3K27me2/H3K27me3 demethylase activity	Histone lysine demethylase PHF8	Homo sapiens (human)
histone H3K36me/H3K36me2 demethylase activity	Histone lysine demethylase PHF8	Homo sapiens (human)
histone H3K9me/H3K9me2 demethylase activity	Histone lysine demethylase PHF8	Homo sapiens (human)
transcription coregulator activity	Histone lysine demethylase PHF8	Homo sapiens (human)
protein binding	Lysine-specific demethylase 2A	Homo sapiens (human)
zinc ion binding	Lysine-specific demethylase 2A	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 2A	Homo sapiens (human)
unmethylated CpG binding	Lysine-specific demethylase 2A	Homo sapiens (human)
histone H3K36 demethylase activity	Lysine-specific demethylase 2A	Homo sapiens (human)
histone H3K36me/H3K36me2 demethylase activity	Lysine-specific demethylase 2A	Homo sapiens (human)
transcription coregulator activity	Lysine-specific demethylase 2A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Lysine-specific demethylase 4E	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 4E	Homo sapiens (human)
chromatin	Lysine-specific demethylase 4E	Homo sapiens (human)
nucleus	Lysine-specific demethylase 4E	Homo sapiens (human)
nucleus	Lysine-specific demethylase 6B	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 6B	Homo sapiens (human)
MLL3/4 complex	Lysine-specific demethylase 6B	Homo sapiens (human)
nucleus	Lysine-specific demethylase 6A	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 6A	Homo sapiens (human)
MLL3/4 complex	Lysine-specific demethylase 6A	Homo sapiens (human)
histone methyltransferase complex	Lysine-specific demethylase 6A	Homo sapiens (human)
fibrillar center	Lysine-specific demethylase 4A	Homo sapiens (human)
nucleus	Lysine-specific demethylase 4A	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 4A	Homo sapiens (human)
cytosol	Lysine-specific demethylase 4A	Homo sapiens (human)
pericentric heterochromatin	Lysine-specific demethylase 4A	Homo sapiens (human)
nucleus	Lysine-specific demethylase 4A	Homo sapiens (human)
chromatin	Lysine-specific demethylase 4A	Homo sapiens (human)
cytosol	Gamma-butyrobetaine dioxygenase	Homo sapiens (human)
extracellular exosome	Gamma-butyrobetaine dioxygenase	Homo sapiens (human)
mitochondrion	Gamma-butyrobetaine dioxygenase	Homo sapiens (human)
nucleus	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleolus	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleus	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleus	Lysine-specific demethylase 5C	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 5C	Homo sapiens (human)
cytosol	Lysine-specific demethylase 5C	Homo sapiens (human)
nucleus	Lysine-specific demethylase 5C	Homo sapiens (human)
chromatin	Lysine-specific demethylase 5C	Homo sapiens (human)
extracellular region	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
extracellular space	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
nucleus	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
focal adhesion	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
membrane	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
vesicle	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
secretory granule lumen	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
extracellular exosome	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
ficolin-1-rich granule lumen	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein-containing complex	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
nucleus	Lysine-specific demethylase 7A	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 7A	Homo sapiens (human)
nucleolus	Lysine-specific demethylase 7A	Homo sapiens (human)
cytoplasm	Egl nine homolog 1	Homo sapiens (human)
cytosol	Egl nine homolog 1	Homo sapiens (human)
postsynaptic density	Egl nine homolog 1	Homo sapiens (human)
intracellular membrane-bounded organelle	Egl nine homolog 1	Homo sapiens (human)
glutamatergic synapse	Egl nine homolog 1	Homo sapiens (human)
nucleus	Egl nine homolog 1	Homo sapiens (human)
cytoplasm	Egl nine homolog 1	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 4C	Homo sapiens (human)
chromatin	Lysine-specific demethylase 4C	Homo sapiens (human)
pericentric heterochromatin	Lysine-specific demethylase 4C	Homo sapiens (human)
nucleus	Lysine-specific demethylase 4C	Homo sapiens (human)
nucleus	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
nucleoplasm	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
cytoplasm	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
cytosol	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
perinuclear region of cytoplasm	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
cytoplasm	Hypoxia-inducible factor 1-alpha inhibitor	Homo sapiens (human)
nucleus	Histone lysine demethylase PHF8	Homo sapiens (human)
nucleoplasm	Histone lysine demethylase PHF8	Homo sapiens (human)
nucleolus	Histone lysine demethylase PHF8	Homo sapiens (human)
nuclear membrane	Histone lysine demethylase PHF8	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 2A	Homo sapiens (human)
chromosome	Lysine-specific demethylase 2A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (69)

Assay ID	Title	Year	Journal	Article
AID698677	Mixed type inhibition of human KDM2A expressed in Escherichia coli assessed inhibition constant for compound-enzyme-substrate complex using methyl lysine peptide substrate by enzyme kinetic assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698701	Inhibition of human PHF8 expressed in Escherichia coli using methyl lysine peptide substrate by AlphaScreen assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698699	Inhibition of human KDM7A catalytic domain expressed in Escherichia coli by MALDI assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698678	Competitive inhibition of human KDM2A expressed in Escherichia coli using 2-oxoglutarate by enzyme kinetic assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698700	Inhibition of human KDM2A expressed in Escherichia coli using methyl lysine peptide substrate by AlphaScreen assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID770456	Inhibition of KDM7B (unknown origin) by alphascreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
AID770460	Inhibition of KDM7B (unknown origin) using H3K4me3K9me2 and 2-oxoglutarate as substrate after 1 hr by matrix-assisted laser desorption ionization time of flight mass spectrometry	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
AID770454	Inhibition of KDM2A (unknown origin)	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
AID698679	Selectivity ratio of IC50 for human KDM5C to IC50 for human KDM7A	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698698	Inhibition of human KDM3A catalytic domain expressed in Sf9 cells methyl lysine peptide substrate by AlphaScreen assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698685	Selectivity ratio of IC50 for human KDM5C to IC50 for human PHF8	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698687	Selectivity ratio of IC50 for human KDM3A to IC50 for human PHF8	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698689	Selectivity ratio of IC50 for human KDM4E to IC50 for human KDM2A	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID770458	Inhibition of KDM4A (unknown origin) using H3K9me3 peptide and 2-oxoglutarate as substrate after 1 hr by FDH-coupled assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
AID698697	Inhibition of human KDM4E expressed in Escherichia coli using methyl lysine peptide substrate by AlphaScreen assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698686	Selectivity ratio of IC50 for human KDM6B to IC50 for human KDM2A	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID770455	Inhibition of human recombinant KDM6A after 1 hr	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
AID698694	Inhibition of human PHD2 expressed in Escherichia coli by fluorescence based assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID770459	Inhibition of KDM4C (unknown origin) using H3K9me3 peptide and 2-oxoglutarate as substrate after 1 hr by FDH-coupled assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
AID698683	Selectivity ratio of IC50 for human KDM6B to IC50 for human PHF8	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698695	Inhibition of human KDM6B catalytic domain expressed in Escherichia coli using methyl lysine peptide substrate by AlphaScreen assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698684	Selectivity ratio of IC50 for human KDM4E to IC50 for human PHF8	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698693	Inhibition of human FIH expressed in Escherichia coli by MALDI assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID770457	Inhibition of KDM5A (unknown origin) using H3K4me3 peptide and 2-oxoglutarate as substrate after 1 hr by FDH-coupled assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
AID698682	Selectivity ratio of IC50 for human KDM3A to IC50 for human KDM7A	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698681	Selectivity ratio of IC50 for human KDM4E to IC50 for human KDM7A	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698696	Inhibition of human KDM5C catalytic domain expressed in Sf9 cells using methyl lysine peptide substrate by AlphaScreen assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID1543452	Inhibition of N-terminal His6-tagged recombinant Paramecium bursaria chlorella virus 1 CPH expressed in Escherichia coli Rosetta 2 (DE3) cells pre-incubated for 5 mins before 2OG as substrate and Fe2 as co-factor addition in presence of L-ascorbate and me	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Inhibition of a viral prolyl hydroxylase.
AID698691	Inhibition of human KDM2A expressed in Escherichia coli by formaldehyde dehydrogenase coupled assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698690	Selectivity ratio of IC50 for human KDM3A to IC50 for human KDM2A	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698692	Inhibition of human BBOX1 by fluorescence based assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698688	Selectivity ratio of IC50 for human KDM5C to IC50 for human KDM2A	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698680	Selectivity ratio of IC50 for human KDM6B to IC50 for human KDM7A	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID1346141	Human lysine demethylase 2A (1.14.11.- Histone demethylases)	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID1346056	Human lysine demethylase 7A (1.14.11.- Histone demethylases)	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID1346139	Human PHD finger protein 8 (1.14.11.- Histone demethylases)	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	12 (24.49)	18.7374
1990's	9 (18.37)	18.2507
2000's	6 (12.24)	29.6817
2010's	13 (26.53)	24.3611
2020's	9 (18.37)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (1.69%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	1 (1.69%)	0.25%
Other	57 (96.61%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Three Dimensional Evaluation of Nasolabial Changes Following Classic Versus Modified Alar Base Suture After Le Fort I Osteotomy [NCT03636178]		40 participants (Anticipated)	Interventional	2018-09-30	Not yet recruiting
Aesthetic and Functional Results of Alar Base Modifications in Rhinoplasty : A Randomized Clinical Trial [NCT03213548]		50 participants (Anticipated)	Interventional	2017-09-15	Not yet recruiting
The Nasal Changes Affected by 2 Different Alar Base Suture Techniques After Maxillary LeFort I Osteotomy--A Randomized Controlled Trial [NCT01473745]	Phase 2/Phase 3	48 participants (Actual)	Interventional	2011-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT01473745 (3) [back to overview]	1 Nasolabial Angular Parameters
NCT01473745 (3) [back to overview]	14 Nasolabial Linear Parameters
NCT01473745 (3) [back to overview]	Soft and Hard Tissue Landmarks Movement

1 Nasolabial Angular Parameters

2D nasolabial angular parameter: Nasolabial angle (NLA) (The NLA was a two dimensional measurement and was measured at the midsagittal plane with Image J software®) (NCT01473745)
Timeframe: up to post-operation 6 months

Intervention	degree (Mean)
Modified Alar Cinch Suture	3.25
Conventional Alar Base Cinch Suture	2.92

[back to top]

14 Nasolabial Linear Parameters

"baseline characteristics: intercanthulus distance~nasal linear parameters~nasolabial linear parameters" (NCT01473745)
Timeframe: up to post-operation 6 months

Intervention	mm (Mean)
	Intercanthal distance change	nasal height change	nasal length change	nasal tip protrusion change	Nasal width change	Alar base width change	R nostril show vertical dimension change	L nostril show vertical dimension	Columellar length change	Cutaneous height of upper lip change	Overall upper lip height change	Vermilion height of upper lip change	Lower prolabial width change	Upper lip protrusion change
Conventional Alar Base Cinch Suture	-0.62	-0.80	-0.81	0.46	0.13	0.26	-0.27	-0.13	0.97	0.38	0.25	0.55	-0.40	0.41
Modified Alar Cinch Suture	0.04	0.78	0.38	-0.11	0.31	0.62	-0.19	-0.20	0.38	0.81	0.63	0.55	-0.76	-1.88

[back to top]

Soft and Hard Tissue Landmarks Movement

"The investigator measured the movement (1 month minus baseline) of hard tissue landmarks before and after 4-6 weeks maxillary LeFort I osteotomy. The movement (6 months minus baseline) of soft tissue landmarks was measured before and after 6 months of the maxillary LeFort I osteotomy.~The 3D directional movement of each point was measured in the x(transverse), y(vertical), and z (antero-posterior)planes. The positive directional movement of each point in X axis means the point moved left after surgery, and negative directional movement in X axis means the the point moved right after surgery. The positive directional movement in Y axis means the point moved upward after surgery, and negative directional movement in Y axis means the the point moved downward after surgery. The positive directional movement in Z axis means the point moved anteriorly after surgery, and negative directional movement in Z axis means the the point moved posteriorly after surgery." (NCT01473745)
Timeframe: The hard tissue movements were assessed after surgery 4-6 weeks.The soft tissue movements were assessed after surgery 6 months.

Intervention	mm (Mean)
	ANS point X axis	ANS point Y axis	ANS point Z axis	A point X axis	A point Y axis	A point Z axis	UI level X axis	UI level Y axis	UI level Z axis	pronasale X axis	pronasale Y axis	pronasale Z axis	subnasale X axis	subnasale Y axis	subnasale Z axis	labiale suprious X axis	labiale suprious Y axis	labiale suprious Z axis
Conventional Alar Base Cinch Suture	-0.5	-0.32	-0.71	-0.58	-0.95	1.83	0.30	-0.58	1.91	0.14	-0.12	0.08	0.05	0.21	-0.03	0.00	-0.90	0.42
Modified Alar Cinch Suture	0.95	-0.95	0.50	0.22	-1.58	1.11	-0.86	-1.08	2.42	-0.35	-0.29	0.48	-0.67	-0.62	1.08	-0.74	-0.03	-0.03

[back to top]

Substance	Relationship Strength	Studies	Classes	Roles
carbamates [no description available]	2.1	1	amino-acid anion
citric acid, anhydrous Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.	2.21	1	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
oxaloacetic acid Oxaloacetic Acid: A dicarboxylic acid ketone that is an important metabolic intermediate of the CITRIC ACID CYCLE. It can be converted to ASPARTIC ACID by ASPARTATE TRANSAMINASE.. oxaloacetic acid : An oxodicarboxylic acid that is succinic acid bearing a single oxo group.	2.21	1	C4-dicarboxylic acid; oxo dicarboxylic acid	geroprotector; metabolite
pyruvic acid Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.	2.21	1	2-oxo monocarboxylic acid	cofactor; fundamental metabolite
succinic acid Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851). succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.	2.21	1	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent
chlorpyrifos Chlorpyrifos: An organothiophosphate cholinesterase inhibitor that is used as an insecticide and as an acaricide.. chlorpyrifos : An organic thiophosphate that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.	2.1	1	chloropyridine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
saccharin Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.	2.03	1	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic
succinylacetone succinylacetone: inhibitor of heme biosynthesis. 4,6-dioxoheptanoic acid : A dioxo monocarboxylic acid that is heptanoic acid in which oxo groups replace the hydrogens at positions 4 and 6. It is an abnormal metabolite of the tyrosine metabolic pathway and a marker for type 1 tyrosinaemia.	2.07	1	beta-diketone; dioxo monocarboxylic acid	human metabolite
dimethylnitrosamine Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.	6.97	1	nitrosamine	geroprotector; mutagen
gibberellic acid gibberellic acid: RN given refers to (1alpha,2beta,4aalpha,4bbeta,10beta)-isomer; structure. gibberellin A3 : A C19-gibberellin that is a pentacyclic diterpenoid responsible for promoting growth and elongation of cells in plants. Initially identified in Gibberella fujikuroi,it differs from gibberellin A1 in the presence of a double bond between C-3 and C-4.	2.05	1	C19-gibberellin; gibberellin monocarboxylic acid; lactone; organic heteropentacyclic compound	mouse metabolite; plant metabolite
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	1.97	1	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
dicofol Dicofol: An organochlorine insecticide.. dicofol : A tertiary alcohol that is DDT in which the benzylic hydrogen has been replaced by a hydroxy group.	2.1	1	monochlorobenzenes; organochlorine acaricide; tertiary alcohol
captan Captan: One of the phthalimide fungicides.. captan : A dicarboximide that is 3a,4,7,7a-tetrahydrophthalimide in which the hydrogen attached to the nitrogen is replaced by a trichloromethyl group. A non-systemic fungicide introduced in the 1950s, it is widely used for the control of fungal diseases in fruits, vegetables, and ornamental crops.	1.97	1	isoindoles; organochlorine compound; organosulfur compound; phthalimide fungicide	antifungal agrochemical
folpet folpet : A member of the class of phthalimides that is phthalimide in which the hydrogen attached to the nitrogen is replaced by a trichloromethylthio group. An agricultural fungicide, it has been used to control mildew, leaf spot, and other diseases in crops sice the 1950s.	1.97	1	organochlorine compound; organosulfur compound; phthalimide fungicide	antifungal agrochemical
indolebutyric acid indolebutyric acid: RN given refers to parent cpd. indole-3-butyric acid : A indol-3-yl carboxylic acid that is butanoic acid carrying a 1H-indol-3-yl substituent at position 1.	1.95	1	indol-3-yl carboxylic acid	auxin; plant hormone; plant metabolite
ditiocarb Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.	2.1	1	dithiocarbamic acids	chelator; copper chelator
2,4-pyridinedicarboxylic acid lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4.	2.53	2	pyridinedicarboxylic acid
phosmet Phosmet: An organothiophosphorus insecticide that has been used to control pig mange.	1.97	1	organic thiophosphate; organothiophosphate insecticide; phthalimides	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor
chlormequat Chlormequat: A plant growth regulator that is commonly used on ornamental plants.. chlormequat : A quaternary ammonium ion that is choline in which the hydroxy group has been replaced by a chlorine. Its salts (particularly the chloride salt, known as chlormequat chloride) are used as plant growth retardants.	2.4	2	quaternary ammonium ion	plant growth retardant
quinomethionate quinomethionate: an ingredient of Morestan. quinomethionate : A dithioloquinoxaline that results from the formal condensation of 6-methylquinoxaline-2,3-dithiol with phosgene. It has been used as a fungicide and acaricide for the control of mites and powdery mildew on citrus, vegetables, and walnuts, but is not approved for use in the EU.	1.97	1	dithioloquinoxaline; quinoxaline acaricide; quinoxaline antifungal agent	agrochemical
chlorpyrifos-methyl chlorpyrifos-methyl : An organic thiophosphate that is O,O-dimethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.	2.1	1	chloropyridine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
manganese Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.	2.1	1	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
titanium Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.	2.03	1	titanium group element atom
titanium dioxide titanium dioxide: used medically as protectant against externally caused irritation & sunlight; high concentrations of dust may cause irritation to respiratory tract; RN given refers to titanium oxide (TiO2); structure. titanium dioxide : A titanium oxide with the formula TiO2. A naturally occurring oxide sourced from ilmenite, rutile and anatase, it has a wide range of applications.	2.03	1	titanium oxides	food colouring
benomyl [no description available]	1.97	1	aromatic amide; benzimidazole fungicide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	acaricide; anthelminthic drug; antifungal agrochemical; microtubule-destabilising agent; tubulin modulator
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.21	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
triclopyr trichlopyr : A monocarboxylic acid that is (pyridin-2-yloxy)acetic acid substituted by chloro groups at positions 3, 5 and 6. It is an agrochemical used as a herbicide.	2.03	1	aromatic ether; chloropyridine; monocarboxylic acid	agrochemical; environmental contaminant; herbicide; xenobiotic
propiconazole Orbit: Bony cavity that holds the eyeball and its associated tissues and appendages.	1.97	1	conazole fungicide; cyclic ketal; dichlorobenzene; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
dimethylhydrazines Dimethylhydrazines: Hydrazines substituted with two methyl groups in any position.	2.66	3
ammonium peroxydisulfate ammonium persulfate : An inorganic ammonium salt in which two of the terminal hydroxy groups of peroxydisulfuric acid are deprotonated and associated with ammonium ions as counter-cations.	2.03	1
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.11	1	D-glucopyranose	epitope; mouse metabolite
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.41	2	1,2,3-triazole
prochloraz Mirage: a feldspathic porcelain that can be etched & bonded to the tooth. prochloraz : A member of the class of ureas that is 1H-imidazole-1-carboxamide substituted by a propyl and a 2-(2,4,6-trichlorophenoxy)ethyl group at the amino nitrogen atom. A fungicide active against a wide range of diseases affecting field crops, fruit, turf and vegetables.	1.97	1	amide fungicide; aromatic ether; conazole fungicide; imidazole fungicide; imidazoles; trichlorobenzene; ureas	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
bromates Bromates: Negative ions or salts derived from bromic acid, HBrO3.	2.03	1	bromine oxoanion; monovalent inorganic anion
cadmium telluride cadmium telluride: used in radiation monitoring device	2.1	1
dihydrel [no description available]	1.97	1
hydrel Hydrel: mp 91-93 degrees C; white crystalline substance soluble in H2O, MeOH, EtOH	1.97	1
d-2-hydroxyglutarate (R)-2-hydroxyglutaric acid : The (R)-enantiomer of 2-hydroxyglutaric acid.	2.21	1	2-hydroxyglutaric acid	algal metabolite
alpha-hydroxyglutarate, (l)-isomer [no description available]	2.21	1	2-hydroxyglutaric acid
stevioside stevioside: Kaurene glucoside from leaves of Stevia rebaudiana; 300 times as sweet as sugar. stevioside : A diterpene glycoside that is rubusoside in which the hydroxy group at position 2 of the allylic beta-D-glucoside has been converted to the corresponding beta-D-glucoside. It is a natural herbal sweetener that is 250-300 times sweeter than sucrose (though with a bitter aftertaste), extracted from the Stevia rebaudiana plant native to South America.. diterpene glycoside : A terpene glycoside in which the terpene moiety is a diterpenoid.	2.11	1	beta-D-glucoside; bridged compound; diterpene glycoside; ent-kaurane diterpenoid; tetracyclic diterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; hypoglycemic agent; plant metabolite; sweetening agent
fumaric acid fumaric acid: see also record for ferrous fumarate; use FUMARATES for general fumaric acid esters. fumaric acid : A butenedioic acid in which the C=C double bond has E geometry. It is an intermediate metabolite in the citric acid cycle.	2.21	1	butenedioic acid	food acidity regulator; fundamental metabolite; geroprotector
steviol steviol: aglucon of stevioside; RN given refers to (4alpha)-isomer. steviol : An ent-kaurane diterpenoid that is 5beta,8alpha,9beta,10alpha-kaur-16-en-18-oic acid in which the hydrogen at position 13 has been replaced by a hydroxy group.	2.11	1	bridged compound; ent-kaurane diterpenoid; monocarboxylic acid; tertiary allylic alcohol; tetracyclic diterpenoid	antineoplastic agent
5-carboxy-8-hydroxyquinoline 5-carboxy-8-hydroxyquinoline: a JmjC histone demethylase inhibitor; structure in first source	2.21	1	quinolines
aconitic acid cis-aconitic acid : The cis-isomer of aconitic acid.	2.21	1	aconitic acid	fundamental metabolite
oxalylglycine oxalylglycine: structure given in first source. N-oxalylglycine : An amino dicarboxylic acid that is iminodiacetic acid with an oxo substituent. It is used as an inhibitor of alpha-ketoglutarate dependent (EC 1.14.11.*) enzymes.	2.53	2	amino dicarboxylic acid; N-acylglycine	EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor
ginsenosides ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.	1.96	1
dimethyldithiocarbamate Dimethyldithiocarbamate: A chemical that acts as a dopamine beta-hydroxylase inhibitor. Its salts are agricultural fungicides. It is inferior to diethyldithiocarbamate as a chelating agent.. dimethyldithiocarbamate : A member of the class of dithiocarbamate anions resulting from the removal of the proton from the dithiocarbamic acid moiety of dimethyldithiocarbamic acid. The major species at pH 7.3.	2.1	1	dithiocarbamate anions
ammonium sulfate Ammonium Sulfate: Sulfuric acid diammonium salt. It is used in CHEMICAL FRACTIONATION of proteins.. ammonium sulfate : An inorganic sulfate salt obtained by reaction of sulfuric acid with two equivalents of ammonia. A high-melting (decomposes above 280degreeC) white solid which is very soluble in water (70.6 g/100 g water at 0degreeC; 103.8 g/100 g water at 100degreeC), it is widely used as a fertilizer for alkaline soils.	2.03	1	ammonium salt; inorganic sulfate salt	fertilizer
tellurium Tellurium: An element that is a member of the chalcogen family. It has the atomic symbol Te, atomic number 52, and atomic weight 127.60. It has been used as a coloring agent and in the manufacture of electrical equipment. Exposure may cause nausea, vomiting, and CNS depression.	2.1	1	chalcogen; metalloid atom
paclobutrazol paclobutrazol: RN given refers to (R,R)-(+-)-isomer. paclobutrazol : A racemate comprising equimolar amounts of (2R,3R)- and (2S,3S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol. It acts as a plant-growth retardant and fungicide via inhibition of gibberellin biosynthesis.	2.06	1
beta-escin [no description available]	1.96	1
fg-4592 roxadustat: structure in first source. roxadustat : An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid. It is an inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH).	2.21	1	aromatic ether; isoquinolines; N-acylglycine	EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor
chlorophyll a Chlorophyll: Porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms.. chlorophyll : A family of magnesium porphyrins, defined by the presence of a fifth ring beyond the four pyrrole-like rings. The rings can have various side chains which usually include a long phytol chain.	1.96	1	chlorophyll; methyl ester	cofactor
potassium bromate potassium bromate: used as bread improver	2.03	1	bromate salt; potassium salt	flour treatment agent
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid [no description available]	2.21	1	quinolines
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid [no description available]	2.21	1	organonitrogen heterocyclic compound
bay 85-3934 [no description available]	2.21	1
gibberellins [no description available]	2.77	3
imidacloprid imidacloprid: systemic & contact insecticide exhibiting low mammalian toxicity; structure given in first source; it is one of the neonicotinoid insecticides, which acts as an antagonist by binding to postsynaptic nicotinic receptors in the insect central nervous system. imidacloprid : An imidazolidine that is N-nitroimidazolidin-2-imine bearing a (6-chloro-3-pyridinyl)methyl substituent at position 1.	2.1	1	imidacloprid; imidazolidines; monochloropyridine	environmental contaminant; genotoxin; neonicotinoid insectide; nicotinic acetylcholine receptor agonist; xenobiotic

Condition	Relationship Strength	Studies
Plasmodium falciparum Malaria [description not available]	2.1	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Arthritis, Degenerative [description not available]	2.6	1
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	2.6	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.7	3
Cancer of Pancreas [description not available]	2.03	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.03	1
Diseases, Occupational [description not available]	2	1
Experimental Neoplasms [description not available]	1.98	1
Benign Neoplasms [description not available]	2.66	3
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.66	3

daminozide

Description

Cross-References

Synonyms (99)

Research Excerpts

Compound-Compound Interactions

Bioavailability

Drug Classes (1)

Protein Targets (23)

Potency Measurements

Inhibition Measurements

Biological Processes (94)

Molecular Functions (57)

Ceullar Components (26)

Bioassays (69)

Research

Studies (49)

Study Types

Clinical Trials (3)

Trial Overview

Trial Outcomes

1 Nasolabial Angular Parameters

14 Nasolabial Linear Parameters

Soft and Hard Tissue Landmarks Movement

daminozide

Description

Cross-References

Synonyms (99)

Research Excerpts

Compound-Compound Interactions

Bioavailability

Drug Classes (1)

Protein Targets (23)

Potency Measurements

Inhibition Measurements

Biological Processes (94)

Molecular Functions (57)

Ceullar Components (26)

Bioassays (69)

Research

Studies (49)

Study Types

Clinical Trials (3)

Trial Overview

Trial Outcomes

1 Nasolabial Angular Parameters

14 Nasolabial Linear Parameters

Soft and Hard Tissue Landmarks Movement

Related Drugs (59)

Related Conditions (16)